Publication

In vivo evaluation of [F-18]FEAnGA-Me: a PET tracer for imaging beta-glucuronidase (beta-GUS) activity in a tumor/inflammation rodent model

Antunes, I. F., Haisma, H. J., Elsinga, P. H., Sijbesma, J. W. A., van Waarde, A., Willemsen, A. T. M., Dierckx, R. A. & de Vries, E. F. J., Aug-2012, In : Nuclear Medicine and Biology. 39, 6, p. 854-863 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Antunes2012e

    Final publisher's version, 957 KB, PDF document

DOI

Introduction: The PET tracer, 1-O-(4-(2-fluoroethyl-carbamoyloxymethyl)-2-nitrophenyl)-O-beta-D-glucopyronuronate ([F-18]FEAnGA), was recently developed for PET imaging of extracellularl beta-glucuronidase (beta-GUS). However,[F-18]FEAnGA exhibited rapid renal clearance, which resulted in a relatively low tracer uptake in the tumor. To improve the pharmacokinetics of [F-18]FEAnGA, we developed its more lipophilic methyl ester analog, [F-18]FEAnGA-Me.

Methods: [F-18]FEAnGA-Me was obtained by alkylation of the O-protected glucuronide methyl ester precursor with [F-18]-fluoroethylamine ([F-18]FEA), followed by removal of the acetate protecting groups with NaOMe/MeOH. The PET tracer was evaluated by in vitro and in vivo studies.

Results: [F-18]FEAnGA-Me was obtained in 5%-10% overall radiochemical yield. It is 10-fold less hydrophilic than [F-18]FEAnGA and it is stable in PBS and in the presence of beta-GUS for 1 h. However, in the presence of esterase or plasma [F-18]FEAnGA-Me is converted to [F-18]FEAnGA, and subsequently converted to [F-18]FEA by beta-GUS. MicroPET studies in Wistar rats bearing a C6 glioma and a sterile inflammation showed similar uptake in tumors after injection of either [F-18]FEAnGA-Me or [F-18]FEAnGA. Both tracers had a rapid two-phase clearance of total plasma radioactivity with a half-life of 1 and 8 min. The [F-18]FEAnGA fraction generated from [F-18]FEAnGA-Me by in vivo hydrolysis had a circulation half-life of 1 and 11 min in plasma. Similar distribution volume in the viable part of the tumor was found after injection of either [F-18]FEAnGA-Me or [F-18]FEAnGA.

Conclusion: The imaging properties of [F-18]FEAnGA-Me were not significantly better than those of [F-18]FEAnGA. Therefore, other strategies should be applied in order to improve the kinetics of these tracers. (C) 2012 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)854-863
Number of pages10
JournalNuclear Medicine and Biology
Volume39
Issue number6
Publication statusPublished - Aug-2012

    Keywords

  • Prodrug, beta-glucuronidase, Pharmacokinetics, PET, Necrosis and inflammation, TUMOR-SELECTIVE CHEMOTHERAPY, HUMAN OVARIAN-CANCER, DIFFERENTIATING TUMOR, PRODRUG DOX-GA3, GENE-THERAPY, INFLAMMATION

View graph of relations

Download statistics

No data available

ID: 5626969